{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T04:25:20Z","timestamp":1784435120982,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.biopha.2024.116895","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:54:23Z","timestamp":1718326463000},"page":"116895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Synergistic activities of Panobinostat and doxorubicin in soft tissue sarcomas"],"prefix":"10.1016","volume":"176","author":[{"given":"Yingjun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie W.C.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kingsley","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert H.","family":"Loong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2024.116895_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-3329-2-14","article-title":"The epidemiology of sarcoma","volume":"2","author":"Burningham","year":"2012","journal-title":"Clin. Sarcoma Res."},{"key":"10.1016\/j.biopha.2024.116895_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1199292","article-title":"Chemotherapeutic drugs for soft tissue sarcomas: a review","volume":"14","author":"Tian","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116895_bib3","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/cancers15020514","article-title":"Trends in overall survival among patients treated for sarcoma at a large tertiary cancer center between 1986 and 2014","volume":"15","author":"Stricker","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116895_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ctrv.2017.06.006","article-title":"Therapeutic applications of histone deacetylase inhibitors in sarcoma","volume":"59","author":"Tang","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2024.116895_bib5","first-page":"2527","article-title":"Immunohistochemical characterization of histone deacetylase as a potential prognostic marker and therapeutic target in endometrial stromal sarcoma","volume":"36","author":"Baek","year":"2016","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2024.116895_bib6","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/s10637-022-01239-1","article-title":"Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas","volume":"40","author":"Zhang","year":"2022","journal-title":"Investig. N. Drugs"},{"issue":"15","key":"10.1016\/j.biopha.2024.116895_bib7","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","article-title":"SynergyFinder: a web application for analyzing drug combination dose\u2013response matrix data","volume":"33","author":"Ianevski","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2024.116895_bib8","unstructured":"Chou T., Martin N. (2005) CompuSyn for Drug Combinations: Pc Software and User\u2019s Guide: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC50 and ED50 and LD50 values. ComboSyn, Paramus, NJ."},{"issue":"21","key":"10.1016\/j.biopha.2024.116895_bib9","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1158\/0008-5472.CAN-15-0418","article-title":"NUP160\u2013SLC43A3 is a novel recurrent fusion oncogene in angiosarcoma","volume":"75","author":"Shimozono","year":"2015","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2024.116895_bib10","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1038\/leu.2009.182","article-title":"The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair","volume":"23","author":"Maiso","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biopha.2024.116895_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1183\/09031936.00037310","article-title":"Valproate\u2013doxorubicin: promising therapy for progressing mesothelioma. A phase II study.","volume":"37","author":"Scherpereel","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.biopha.2024.116895_bib12","doi-asserted-by":"crossref","first-page":"993","DOI":"10.4161\/hv.23800","article-title":"Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation","volume":"9","author":"Rasmussen","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"issue":"8","key":"10.1016\/j.biopha.2024.116895_bib13","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/1535-7163.MCT-09-0138","article-title":"The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer","volume":"8","author":"Crisanti","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.biopha.2024.116895_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169485","article-title":"Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models","volume":"12","author":"Hennika","year":"2017","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.biopha.2024.116895_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126566","article-title":"Molecular mechanism of the cell death induced by the histone deacetylase pan inhibitor LBH589 (Panobinostat) in Wilms tumor cells","volume":"10","author":"Yan-Fang","year":"2015","journal-title":"PloS One"},{"issue":"9","key":"10.1016\/j.biopha.2024.116895_bib16","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1002\/cncr.32744","article-title":"Overcoming acquired resistance of EGFR-mutant NSCLC cells to osimertinib by combining osimertinib with the HDAC inhibitor, panobinostat (LBH589)","volume":"126","author":"Zang","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116895_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2490-14-71","article-title":"Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells","volume":"14","author":"Sato","year":"2014","journal-title":"BMC Urol."},{"issue":"2","key":"10.1016\/j.biopha.2024.116895_bib18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.canlet.2014.10.015","article-title":"Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer","volume":"356","author":"Wang","year":"2015","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.biopha.2024.116895_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049277","article-title":"Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer","volume":"7","author":"Lin","year":"2012","journal-title":"PloS One"},{"issue":"6","key":"10.1016\/j.biopha.2024.116895_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1530\/ERC-17-0045","article-title":"Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model","volume":"24","author":"Marano","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.biopha.2024.116895_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/704124","article-title":"Management strategies in advanced uterine leiomyosarcoma: focus on trabectedin","volume":"2015","author":"Amant","year":"2015","journal-title":"Sarcoma"},{"issue":"5","key":"10.1016\/j.biopha.2024.116895_bib22","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1053\/j.gastro.2020.07.046","article-title":"Loss of HIF1A from pancreatic cancer cells increases expression of PPP1R1B and degradation of p53 to promote invasion and metastasis","volume":"159","author":"Tiwari","year":"2020","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.biopha.2024.116895_bib23","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.3390\/ijms19123842","article-title":"Low HIF-1\u03b1 and low EGFR mRNA expression significantly associate with poor survival in soft tissue sarcoma patients; the proteins react differently","volume":"19","author":"Rot","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2024.116895_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-01617-3","article-title":"Benchmarking of RNA-sequencing analysis workflows using whole-transcriptome RT-qPCR expression data","volume":"7","author":"Everaert","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2024.116895_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00251-023-01296-7","article-title":"Comparison between qPCR and RNA-seq reveals challenges of quantifying HLA expression","volume":"75","author":"Aguiar","year":"2023","journal-title":"Immunogenetics"},{"issue":"2","key":"10.1016\/j.biopha.2024.116895_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2024.116895_bib27","unstructured":"Chow A. (2010) Cell Cycle Control by Oncogenes and Tumor Suppressors: Driving the."},{"issue":"44","key":"10.1016\/j.biopha.2024.116895_bib28","doi-asserted-by":"crossref","first-page":"77254","DOI":"10.18632\/oncotarget.20460","article-title":"Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines","volume":"8","author":"Bernhart","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2024.116895_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep02640","article-title":"Inhibition of Plk1 and cyclin B1 expression results in panobinostat-induced G2 delay and mitotic defects","volume":"3","author":"Prystowsky","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116895_bib30","first-page":"5150","article-title":"Effects of histone deacetylase inhibitor panobinostat (LBH589) on bone marrow mononuclear cells of relapsed or refractory multiple myeloma patients and its mechanisms","volume":"23","author":"Ma","year":"2017","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"issue":"2","key":"10.1016\/j.biopha.2024.116895_bib31","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.freeradbiomed.2010.11.011","article-title":"Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells","volume":"50","author":"Pettazzoni","year":"2011","journal-title":"Free Radic. Biol. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:07:28Z","timestamp":1781651248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224007790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":31,"alternative-id":["S0753332224007790"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116895","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic activities of Panobinostat and doxorubicin in soft tissue sarcomas","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116895"}}